⏸️ BFBIO: HOLD Signal (6/10) – Financial Results for the Quarter Ended 2025-09-30

📌 Key Takeaways

• 🚀 Revenue increased by 75.4% YoY, from Rs. 1,386.37 million to Rs. 2,432.29 million.
• 💰 Gross profit surged by 84.1% YoY, from Rs. 563.83 million to Rs. 1,038.33 million.
• ⚠️ Selling and distribution expenses increased significantly from Rs. 304.87 million to Rs. 709.17 million.
• 📈 Profit from operations rose by 34.2% YoY, from Rs. 221.26 million to Rs. 297.05 million.
• 📉 Finance costs decreased by 24.7% YoY, from Rs. 35.03 million to Rs. 26.39 million.
• ✅ Profit before income tax increased by 47.5% YoY, from Rs. 181.59 million to Rs. 267.89 million.
• 📊 Income tax expense increased by 63.4% YoY, from Rs. 66.31 million to Rs. 108.37 million.
• 🌟 Profit after taxation increased by 38.4% YoY, from Rs. 115.27 million to Rs. 159.52 million.
• 💲 Earnings per share (EPS) remained relatively constant at Rs. 1.81 compared to Rs. 1.82 last year.
• 💸 Cash generated from operations increased from Rs. 73.50 million to Rs. 131.21 million.
• 🧱 Total assets increased from Rs. 8,158.53 million to Rs. 8,733.56 million.
• 🌱 Unappropriated profit increased from Rs. 2,616.77 million to Rs. 2,776.29 million.

🎯 Investment Thesis

HOLD. BFBIO has shown strong revenue growth and improved profitability. However, increased operating expenses and income tax expenses need to be monitored. Given the mixed signals, it is prudent to maintain a HOLD rating. The price target should be revised upon further analysis of cost management and market dynamics.